Loria Pharmaceutical v. Mezzancello: Filler Patent Dispute Ends in Dismissal

Introduction

A pharmaceutical patent infringement action filed in the Southern District of Florida concluded on January 16, 2026, when Loria Pharmaceutical, LLC and defendant Mark Mezzancello jointly stipulated to dismiss the case with prejudice. Filed on February 21, 2024, Case No. 9:24-cv-80198 centered on U.S. Patent No. 9,993,578 B1—a patent covering a pharmaceutical filler product—and ran nearly two full years before the parties reached a negotiated resolution.

Dismissals with prejudice following joint stipulation are a hallmark of settled patent disputes, signaling that the parties reached a private resolution that precluded any refiling on the same claims. For patent attorneys, IP professionals, and R&D teams operating in the pharmaceutical and medical aesthetics sectors, this case offers instructive lessons: about litigation duration, strategic use of joint stipulation, and the commercial stakes tied to filler-related pharmaceutical patents. The outcome also reflects a broader trend in pharmaceutical patent litigation—protracted district court proceedings that ultimately resolve without judicial determination on the merits.

Case Overview

The Parties

The Patent at Issue

The patent in dispute is U.S. Patent No. 9,993,578 B1 (Application No. 15/405,240). The patent covers technology in the **filler** product space—likely relating to formulation, composition, or delivery of pharmaceutical or aesthetic filler materials. Patent No. 9,993,578 was issued by the USPTO and represents a granted, presumably enforceable right at the time of filing. Practitioners can review the full claim set via the USPTO Patent Full-Text Database.

The Accused Product

The accused product category is identified as **”Filler”**—a commercially significant product type in pharmaceutical and medical aesthetics markets. Filler products, particularly injectable dermal fillers, represent a multi-billion-dollar global market, making patent exclusivity in this space highly valuable and litigation over infringement commercially consequential.

Legal Representation

Plaintiff’s Counsel: Allison R. Tramontana, Edward L. White, Jacob Lawrence Phillips, James J. Kozuch, and Joshua Robert Jacobson, representing through Caesar Rivise PC, Edward L. White PC, and Jacobson Phillips PLLC—a multi-firm team signaling a well-resourced litigation strategy.

Defendant’s Counsel: Cole Younger Carlson, Jason A. Stewart, and Stefan Vaughn Stein, representing through Carlson IP Law, LLC, SteinPatent PA, and The Law Offices of Neal Brickman, P.C.—similarly a multi-firm defense coalition.

Litigation Timeline & Procedural History

The action was filed in the U.S. District Court for the Southern District of Florida, presided over by Chief Judge Ed Artau, based in West Palm Beach. Venue selection in the Southern District of Florida is strategically notable: the district has seen increased pharmaceutical and biotechnology patent filings and is considered a plaintiff-accessible forum with experienced IP judiciary.

At 695 days, the litigation duration falls within the range typical for resolved district court patent cases—neither an expedited resolution nor an outlier in length. The case resolved without proceeding to trial, as the parties filed a Joint Stipulation of Dismissal With Prejudice captured in Docket Entry [78]. The volume of docket activity reaching entry 78 suggests meaningful pre-settlement litigation, likely including pleadings, discovery exchanges, and possibly motion practice, before the parties negotiated an exit. Specific interim milestones—such as claim construction hearings, Markman rulings, or summary judgment motions—are not disclosed in the available case data.

The Verdict & Legal Analysis

Outcome

On January 16, 2026, Chief Judge Ed Artau entered an order dismissing the case with prejudice pursuant to the parties’ joint stipulation. The court’s order specified:

• • The case is dismissed with prejudice
• • Each party bears its own costs, expenses, and attorneys’ fees
• • All pending motions denied as moot; all deadlines terminated

The dismissal with prejudice is legally significant: it operates as a final adjudication on the merits for preclusion purposes, meaning Loria Pharmaceutical cannot refile the same infringement claims against Mezzancello based on the same patent and accused product. Critically, no damages were awarded by the court, and no injunctive relief was issued—consistent with a privately negotiated resolution rather than a judicial determination.

The mutual fee-bearing provision—each party absorbs its own legal costs—is standard in negotiated patent dismissals and suggests neither party achieved a decisive enough outcome to justify a fee-shifting argument under 35 U.S.C. § 285 (exceptional case standard).

Verdict Cause Analysis

The case was brought as a straightforward infringement action under the Patent Act. Because the matter resolved through joint stipulation rather than judicial ruling, no public record exists of claim construction findings, infringement determinations, or validity challenges adjudicated by the court. This limits external analysis of the legal merits but does not diminish the strategic significance of the resolution pattern.

The involvement of specialized patent IP boutiques on both sides—including SteinPatent PA and Caesar Rivise PC, firms with dedicated patent litigation practices—suggests vigorous advocacy throughout the pre-settlement period. The deployment of multiple law firms by each party reflects the complexity and commercial stakes of the dispute.

Legal Significance

Because dismissal occurred by stipulation rather than judicial opinion, this case carries no direct precedential value for claim construction or infringement doctrine in the filler pharmaceutical space. However, it contributes to the empirical record of how pharmaceutical filler patent disputes resolve at the district court level—and underscores the continued strategic utility of settlement before trial. Cases with individual defendants, as here, often present unique settlement dynamics distinct from corporate defendant cases, including personal financial exposure considerations that may accelerate resolution.

Industry & Competitive Implications

The pharmaceutical filler market—encompassing injectable aesthetics, tissue engineering, and drug-delivery fillers—is a high-value IP battleground. Patent protection in this space governs product exclusivity, licensing economics, and competitive moat for both large pharmaceutical companies and emerging biotech entities.

This case reflects several broader market trends:

• • Individual-defendant enforcement actions are becoming more common as patent holders pursue infringers across corporate and personal boundaries, particularly where individual developers or former employees commercialize competing formulations.
• • Multi-firm litigation teams on both sides signal that even cases involving individual defendants can attract sophisticated, well-resourced advocacy when commercially significant patents are at stake.
• • Pre-trial settlement remains the modal outcome in pharmaceutical patent disputes, preserving confidentiality around licensing terms, royalty rates, and future product development rights.

Companies developing or commercializing filler products—dermal fillers, injectable biomaterials, or pharmaceutical delivery matrices—should treat U.S. Patent No. 9,993,578 B1 as an active IP risk factor requiring monitoring, particularly as Loria Pharmaceutical has demonstrated willingness to assert its rights in federal court.